title: [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
abstract: Determination of the effectiveness and safety of different dosing regimens during the day (in the morning or at bedtime) combination therapy including azilsartan medoxomil in patients with essential hypertension and metabolic syndrome (MS).
  
  
  
  The study included 60 patients with uncontrolled hypertension and MS (age median - 59 (54-65) years). Patients were randomized in two groups: group 1 (n=30) received azilsartan medoxomil 40 mg/day, and indapamide retard 1,5 mg/day in the morning; group 2 (n=30)- azilsartan medoxomoil 40 mg at bedtime and indapamide retard 1,5 mg in the morning. All patients at baseline, and after 4 and 12weeks assessed levels of office blood pressure (BP), heart rate (HR); at baseline and after 12 weeks was conducted ambulatory BPmonitoring (ABPM). Evaluated the main indicators of circadian blood pressure profile, as well as the central aortic pressure (CAP) and the rigidity of the vascular wall: systolic, diastolic, and mean arterial pressure in the aorta, aortic augmentation index, pulse wave velocity in the aorta, the augmentation index. Study results were processed using the program Statistica 6.1 by methods nonparametric statistics.
  
  
  
  Regardless of the regimen used azilsartan destination as part of combination therapy after 4 weeks showed a significant (p<0.05) reduction in SBP and DBP. After 12 weeks of observation target blood pressure was recorded 27 (90%) patients of group 1 and 29 (96.7%)- group2. As a result of ABPM after 12 weeks of treatment in both groups showed a statistically significant (p<0.05) improvement in all parameters investigated. However, positive changes such indicators as an index time of hypertension in the day and night hours, SBP, DBP, and BP variability during the night, the morning rise of systolic as well as the speed of morning rise in SBP and DBP were more pronounced in the appointment azilsartan medoxomil at bedtime compared to morning reception. The use of both treatment regimens provided significant (p<0.05) increase frequency registration profile dippear and reduction - non-dipper. Importantly, irrespective of the time of taking the drugs in both groups occurred significant (p <0.05), and a comparable improvement in rigidity and CAP vascular wall.
  
  
  
  When combined with essential hypertension and MS azilsartana use of combination drug therapy provided achievement of the target values of blood pressure in the majority of patients, a significant improvement in the main indicators of ABPM, CAP, and the rigidity of the vascular wall, as well as the normalization of daily profile of blood pressure in the majority of patients, regardless of dosing regimen during the day. However, the combination of indapamide retard morning - azilsartan medoxomil at bedtime accompanied by a significantly greater positive changes most ABPM parameters, especially at night.
authors.affiliation: Kuban State Medical University, Hospital Therapy Department, Krasnodar, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Skibitskiy
authors.affiliation: Kuban State Medical University, Hospital Therapy Department, Krasnodar, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Fendrikova
authors.affiliation: Kuban State Medical University, Hospital Therapy Department, Krasnodar, Russia.
authors.forename: D V
authors.initials: DV
authors.lastname: Sirotenko
authors.affiliation: Kuban State Medical University, Hospital Therapy Department, Krasnodar, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Skibitskiy
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D062186:Arterial Pressure; D001562:Benzimidazoles / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D055870:Drug Chronotherapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D010069:Oxadiazoles / Q000008:administration & dosage*; D063177:Pulse Wave Analysis; D011897:Random Allocation
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D010069:Oxadiazoles; D007190:Indapamide; C557413:azilsartan medoxomil
keywords: azilsartan medoxomil; essential hypertension; hronopharmacotherapy; metabolic syndrome